CA2350635A1 - Therapeutic product and its use - Google Patents

Therapeutic product and its use Download PDF

Info

Publication number
CA2350635A1
CA2350635A1 CA002350635A CA2350635A CA2350635A1 CA 2350635 A1 CA2350635 A1 CA 2350635A1 CA 002350635 A CA002350635 A CA 002350635A CA 2350635 A CA2350635 A CA 2350635A CA 2350635 A1 CA2350635 A1 CA 2350635A1
Authority
CA
Canada
Prior art keywords
tramadol
enantiomer
product according
racemic
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002350635A
Other languages
English (en)
French (fr)
Inventor
Hazel Bardsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9826535.8A external-priority patent/GB9826535D0/en
Priority claimed from GBGB9826537.4A external-priority patent/GB9826537D0/en
Priority claimed from GBGB9826536.6A external-priority patent/GB9826536D0/en
Application filed by Individual filed Critical Individual
Publication of CA2350635A1 publication Critical patent/CA2350635A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002350635A 1998-12-02 1999-12-02 Therapeutic product and its use Abandoned CA2350635A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9826535.8A GB9826535D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GBGB9826537.4A GB9826537D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GB9826537.4 1998-12-02
GB9826535.8 1998-12-02
GBGB9826536.6A GB9826536D0 (en) 1998-12-02 1998-12-02 Therapeutic product and its use
GB9826536.6 1998-12-02
PCT/GB1999/004021 WO2000032558A1 (en) 1998-12-02 1999-12-02 Therapeutic product and its use

Publications (1)

Publication Number Publication Date
CA2350635A1 true CA2350635A1 (en) 2000-06-08

Family

ID=27269570

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002350635A Abandoned CA2350635A1 (en) 1998-12-02 1999-12-02 Therapeutic product and its use

Country Status (12)

Country Link
EP (1) EP1135361A1 (ja)
JP (1) JP2002531431A (ja)
KR (1) KR20010080364A (ja)
CN (1) CN1329590A (ja)
AU (1) AU1400100A (ja)
BR (1) BR9915873A (ja)
CA (1) CA2350635A1 (ja)
HU (1) HUP0104420A2 (ja)
IL (1) IL142778A0 (ja)
NO (1) NO20012738D0 (ja)
PL (1) PL347542A1 (ja)
WO (1) WO2000032558A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1164601A (en) 1999-11-09 2001-06-06 Darwin Discovery Limited Therapeutic use and formulation
WO2002028383A1 (en) * 2000-10-03 2002-04-11 Penwest Pharmaceuticals Company Delivery system for multi-pharmaceutical active materials at various release rates
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
US6780891B2 (en) 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof
ES2389666T3 (es) 2005-09-09 2012-10-30 Angelini Labopharm, Llc Composición de trazodona para una administración de una vez al día
WO2008100933A2 (en) 2007-02-12 2008-08-21 Dmi Biosciences, Inc. Reducing side effects of tramadol
KR101581289B1 (ko) * 2007-05-31 2015-12-31 세프라코 아이엔시. 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
EP3891150A1 (en) * 2018-12-04 2021-10-13 Metys Pharmaceuticals AG Synergistic compositions comprising-r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
DE69826113T2 (de) * 1997-03-11 2005-01-20 Arakis Ltd., Saffron Walden R- und s- enantiomere getrennteteile enthaltende dosierungsformen
DE19807535A1 (de) * 1998-02-21 1999-08-26 Asta Medica Ag Pharmazeutische Kombinationen mit Tramadol

Also Published As

Publication number Publication date
KR20010080364A (ko) 2001-08-22
NO20012738L (no) 2001-06-01
CN1329590A (zh) 2002-01-02
HUP0104420A2 (en) 2002-08-28
JP2002531431A (ja) 2002-09-24
EP1135361A1 (en) 2001-09-26
WO2000032558A1 (en) 2000-06-08
PL347542A1 (en) 2002-04-08
NO20012738D0 (no) 2001-06-01
BR9915873A (pt) 2001-08-21
AU1400100A (en) 2000-06-19
IL142778A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
Teoh et al. Oral manifestations of illicit drug use
Grond et al. Clinical pharmacology of tramadol
KR19990028983A (ko) 디-트레오-메틸페니데이트 및 다른 약품으로 이루어진 조성물
CA2318921A1 (en) Pharmacological uses of optically pure (+)-bupropion
CA2350635A1 (en) Therapeutic product and its use
NO302736B1 (no) Farmasöytisk preparat omfattende tramadol og ibuprofen
US6297286B1 (en) Therapeutic use and formulation
EP2002828B1 (en) Solid pharmaceutical preparation
Mystakidou et al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics
DE69918322T2 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
WO2000051582A2 (en) Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
EP1697005B1 (en) Combination of flupirtine and tramadol
JPWO2006038339A1 (ja) 固形医薬製剤
CA2423558A1 (en) Delivery system for multi-pharmaceutical active materials at various release rates
KR20050009983A (ko) 트라마돌의 서방성 제제
Likar et al. Challenging the equipotency calculation for transdermal buprenorphine: four case studies
AU2349899A (en) Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
MXPA01005242A (en) Therapeutic product and its use
WO1994021244A1 (en) Method of treating addictive behaviors
US20020032197A1 (en) Methods and compositions for using moclobemide
CA2338326A1 (en) Use of moclobemide and metabolites for treating and preventing substance abuse
RU2506947C2 (ru) Таблетка пролонгированного высвобождения, содержащая теобромин
US20160317662A1 (en) Stable oral pharmaceutical composition
AU2003220743B2 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
KR20070004127A (ko) 공동-남용 가능성의 감소 방법

Legal Events

Date Code Title Description
FZDE Discontinued